IMCIVREE delivered early, significant, and sustained reduction in BMI Z-score1
← Swipe left or right to see all tabs →
BMI Z-score* reduction in patients <18 years of age1†
*A BMI Z-score was used to measure the reduction in BMI in children. A BMI Z-score is a reliable measure of weight in children who are still growing because it accounts for height, age, and gender.2
†Data shown include only patients who received 52 weeks of IMCIVREE at the time of the analysis. Population sizes ranged from 8 to 16, with n=14 at 52 weeks on active treatment. Error bars are the standard deviation (SD).1
‡A clinically significant reduction is generally considered a ≥0.2 reduction in BMI Z-score. A 0.2 reduction is comparable to weight loss of approximately 5%.3
§ATB=active treatment baseline (defined as last measurement before the first dose of IMCIVREE; ie, week 0 for IMCIVREE group and week 14 for placebo group).1
Clinically significant -0.8 mean change in BMI Z-score1
Change in BMI Z-score from baseline in patients <18 years of age after 52 weeks (n=14)1
achieved a clinically significant ≥0.2 reduction* in BMI Z-score1,2
- 100% of patients <12 years of age (n=3) achieved a clinically significant ≥0.2 reduction in BMI Z-score
*A clinically significant reduction is generally considered a ≥0.2 reduction in BMI Z-score. A 0.2 reduction is comparable to weight loss of approximately 5%.2
IMCIVREE significantly reduced the severity of obesity due to BBS1
This chart is a visual representation of what a female child with BBS* who started IMCIVREE at 12 years of age may experience in BMI reduction after 52 weeks, based on data from the phase 3 trial.1-5
*Not an actual patient.
Growth chart is based on females 2 to 20 years of age and is for illustrative purposes only.